Opinion|Videos|May 12, 2025
Applying Trial Data to Real-World Practice in ALK+ NSCLC
Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).
Advertisement
Episodes in this series
Real-World Settings and Evolution of Frontline Therapy
Key Themes:
- Comparison of clinical trial outcomes to real-world patient experiences
- Impact of clinical data (ALINA, CROWN, eXalt3) on frontline therapy choices
- Evolving perspective on frontline therapies for ALK+ NSCLC
Notable Insights:
- Grizzard addressed how well outcomes from trials like CROWN and eXalt3 reflect real-world patient experiences
Dr Dietrich summarized how recent clinical data has changed the landscape of frontline therapies for ALK+ NSCLC
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
3
Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial
4
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
5
